Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Annick D. Van den Abbeele, MD, FACR


Radiology

No Ratings Available - Why Not? Make an Appointment

Physician

  • Chair Emeritus, Department of Imaging
  • Founding Director, Center for Biomedical Imaging in Oncology
  • Co-Director, Tumor Imaging Metrics Core, Dana-Farber/Harvard Cancer Care
  • Institute Physician
  • Associate Professor of Radiology, Harvard Medical School

Centers/Programs

Clinical Interests

  • Cancer imaging
  • Molecular imaging
  • Quantitative tumor metrics
  • Radiotherapy with unsealed sources

Contact Information

  • Office Phone Number617-632-3580
  • Fax617-582-9702

Board Certification:

  • Nuclear Medicine, 1993

Fellowship:

  • Brigham and Women's Hospital/Harvard Medical School, Radiology & Nuclear Medicine
  • Vanderbilt University School of Medicine, Neonatology

Residency:

  • Joint Program in Nuclear Medicine, Harvard Medical School
  • University of Louvain, Pediatrics

Medical School:

  • Catholic University of Louvain

Research

Noninvasive Imaging of Cancer Immunotherapy. Nanotheranostics. 2021; 5(1):90-112.
View in: PubMed

Theranostics: The Role of Quantitative Nuclear Medicine Imaging. Semin Radiat Oncol. 2021 Jan; 31(1):28-36.
View in: PubMed

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res. 2020 04 15; 26(8):1837-1845.
View in: PubMed

Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer. Radiology. 2019 12; 293(3):704-706.
View in: PubMed

Centralized Clinical Trial Imaging Data Management: Practical Guidance from a Comprehensive Cancer Center's Experience. J Digit Imaging. 2019 10; 32(5):849-854.
View in: PubMed

Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. J Nucl Med Technol. 2018 Sep; 46(3):237-244.
View in: PubMed

Development and validation of a new MRI simulation technique that can reliably estimate optimal in vivo scanning parameters in a glioblastoma murine model. PLoS One. 2018; 13(7):e0200611.
View in: PubMed

Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice. Nucl Med Commun. 2018 May; 39(5):417-422.
View in: PubMed

LesionTracker: Extensible Open-Source Zero-Footprint Web Viewer for Cancer Imaging Research and Clinical Trials. Cancer Res. 2017 11 01; 77(21):e119-e122.
View in: PubMed

Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer. Abdom Radiol (NY). 2017 10; 42(10):2513-2520.
View in: PubMed

Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis. Clin Radiol. 2018 02; 73(2):158-167.
View in: PubMed

Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2018 Sep; 47(5):311-316.
View in: PubMed

Immune Modulation Therapy and Imaging: Workshop Report. J Nucl Med. 2018 03; 59(3):410-417.
View in: PubMed

Cancer Imaging Fellowship Training: Utility and Added Value in the Modern Era. J Am Coll Radiol. 2017 10; 14(10):1345-1348.
View in: PubMed

Ovarian Cancer: An Evidence-Based, Easy-to-Use Prediction Rule to Optimize the Use of Follow-up Chest CT. J Am Coll Radiol. 2017 Apr; 14(4):499-508.
View in: PubMed

Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 12; 130(3):495-503.
View in: PubMed

Patterns and Prognostic Importance of Hepatic Involvement in Patients with Serous Ovarian Cancer: A Single-Institution Experience with 244 Patients. Radiology. 2017 Jan; 282(1):160-170.
View in: PubMed

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016 09; 27(9):1794-9.
View in: PubMed

Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. J Am Coll Radiol. 2016 Apr; 13(4):365-71.
View in: PubMed

Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med. 2016 Jan; 41(1):e7-13.
View in: PubMed

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
View in: PubMed

Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT. Clin Nucl Med. 2015 Nov; 40(11):e528-9.
View in: PubMed

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015 Nov 15; 121(22):4007-15.
View in: PubMed

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol. 2015 Aug 20; 33(24):2623-31.
View in: PubMed

Cancer Imaging Training in the 21st Century: An Overview of Where We Are, and Where We Need To Be. J Am Coll Radiol. 2015 Jul; 12(7):714-20.
View in: PubMed

Advanced High-Grade Serous Ovarian Cancer: Frequency and Timing of Thoracic Metastases and the Implications for Chest Imaging Follow-up. Radiology. 2015 Dec; 277(3):733-40.
View in: PubMed

[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. Transl Oncol. 2015 Jun; 8(3):147-53.
View in: PubMed

Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015 Mar-Apr; 35(2):424-37.
View in: PubMed

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
View in: PubMed

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015 Apr; 13(2):113-23.
View in: PubMed

10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist. 2014 May; 19(5):507-14.
View in: PubMed

Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014 Jul; 2(7):632-42.
View in: PubMed

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2014 Apr 20; 32(12):1202-9.
View in: PubMed

Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology. Stat. 2014 Jan 01; 3(1):172-186.
View in: PubMed

Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. Cancer Imaging. 2013 Dec 30; 13(4):626-32.
View in: PubMed

Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer. 2014 Mar 01; 120(5):711-21.
View in: PubMed

What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics. 2013 Nov-Dec; 33(7):2003-17.
View in: PubMed

End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77.
View in: PubMed

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
View in: PubMed

Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol. 2012 Aug; 199(2):367-72.
View in: PubMed

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 01; 30(19):2401-7.
View in: PubMed

Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e647-54.
View in: PubMed

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May 17; 119(20):4597-607.
View in: PubMed

ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med. 2012 Apr; 53(4):567-74.
View in: PubMed

Hereditary cancer syndromes: a radiologist's perspective. AJR Am J Roentgenol. 2011 Dec; 197(6):W1001-7.
View in: PubMed

Imaging in renal cell carcinoma. Hematol Oncol Clin North Am. 2011 Aug; 25(4):687-715.
View in: PubMed

A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol. 2011 May 20; 29(15_suppl):10007.
View in: PubMed

Impact of RECIST 1.1 modifications on clinical trial eligibility. J Clin Oncol. 2011 May 20; 29(15_suppl):e16555.
View in: PubMed

TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). J Clin Oncol. 2011 May 20; 29(15_suppl):527.
View in: PubMed

Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx). J Clin Oncol. 2011 May 20; 29(15_suppl):10050.
View in: PubMed

A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2011 May 20; 29(15_suppl):8511.
View in: PubMed

Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location. J Comput Assist Tomogr. 2011 Mar-Apr; 35(2):217-22.
View in: PubMed

Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer. 2011 Aug 15; 117(16):3860-6.
View in: PubMed

Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011 May; 59(5):856-62.
View in: PubMed

Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011 Apr; 18(4):424-36.
View in: PubMed

Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011 Jan; 196(1):117-22.
View in: PubMed

Imaging of extraosseous myeloma: CT, PET/CT, and MRI features. AJR Am J Roentgenol. 2010 Nov; 195(5):1057-65.
View in: PubMed

CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011 Jan; 18(1):54-62.
View in: PubMed

Adult extragonadal germ cell tumors. AJR Am J Roentgenol. 2010 Oct; 195(4):W274-80.
View in: PubMed

New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010 Sep; 195(3):W221-8.
View in: PubMed

Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer. 2010 Aug 15; 116(16):3835-42.
View in: PubMed

Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010 Aug; 195(2):281-9.
View in: PubMed

Factorial validity of the Supports Intensity Scale (SIS). Am J Intellect Dev Disabil. 2010 Jul; 115(4):327-39.
View in: PubMed

Case report. PET/CT appearance of desmoid tumour of the chest wall. Br J Radiol. 2010 Feb; 83(986):e39-42.
View in: PubMed

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9.
View in: PubMed

Venous thrombosis in an outpatient oncologic center: distribution, type, and comorbidities. Ultrasound Q. 2009 Sep; 25(3):145-50.
View in: PubMed

Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial. AJR Am J Roentgenol. 2009 Aug; 193(2):326-32.
View in: PubMed

CT and PET/CT findings of T-cell lymphoma. AJR Am J Roentgenol. 2009 Aug; 193(2):349-58.
View in: PubMed

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009 Jul; 52(7):767-71.
View in: PubMed

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009 Nov; 20(11):1848-53.
View in: PubMed

ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate (IM) for primary and recurrent operable malignant GIST: Imaging findings and correlation with genotype and GLUT4 expression. J Clin Oncol. 2009 May 20; 27(15_suppl):10552.
View in: PubMed

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3154-60.
View in: PubMed

Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res. 2009 Mar 15; 15(6):1891-7.
View in: PubMed

Infrequent Tumors of the Gastrointestinal Tract Including Gastrointestinal Stromal Tumor (GIST). PET Clin. 2008 Apr; 3(2):207-15.
View in: PubMed

FDG-PET to Measure Response to Targeted Therapy: The Example of Gastrointestinal Stromal Tumor and Imatinib Mesylate (Gleevec). PET Clin. 2008 Jan; 3(1):77-87.
View in: PubMed

F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma. Clin Nucl Med. 2008 Aug; 33(8):545-6.
View in: PubMed

Role of PET/CT scanning in initial and post-treatment assessment of Hodgkin disease. J Natl Compr Canc Netw. 2008 Jul; 6(6):623-32.
View in: PubMed

The impact of large lesions on the RECIST assessment criteria. J Clin Oncol. 2008 May 20; 26(15_suppl):17560.
View in: PubMed

Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. J Clin Oncol. 2008 May 20; 26(15_suppl):10503.
View in: PubMed

Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol. 2008 May 20; 26(15_suppl):5069.
View in: PubMed

Tumor imaging metrics core: A centralized service for standardized tumor measurements at a multi-institutional collaborative cancer center. J Clin Oncol. 2008 May 20; 26(15_suppl):20571.
View in: PubMed

Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET. J Clin Oncol. 2008 May 20; 26(15_suppl):10529.
View in: PubMed

Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma. 2008 May; 49(5):902-9.
View in: PubMed

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
View in: PubMed

Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51.
View in: PubMed

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
View in: PubMed

F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008 Mar 19; 299(11):1315-9.
View in: PubMed

The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist. 2008; 13 Suppl 2:8-13.
View in: PubMed

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007 Dec 15; 370(9604):2011-9.
View in: PubMed

CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol. 2007 Dec; 189(6):W324-30.
View in: PubMed

Impact of acquisition geometry, image processing, and patient size on lesion detection in whole-body 18F-FDG PET. J Nucl Med. 2007 Dec; 48(12):1951-60.
View in: PubMed

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007 Oct 15; 13(20):6175-81.
View in: PubMed

Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405.
View in: PubMed

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul; 5 Suppl 2:S1-29; quiz S30.
View in: PubMed

Imaging of Venous Thrombosis in Oncologic Patients. American Journal of Roentgenology(AJR). 2007; 188(5):E136-A115.

Missed Metastases-Causes and Clinical Relevance. American Journal of Roentgenology(AJR). 2007; 188(5):E145-A115.

Malignant Melanoma - Not Just Skin Deep!. American Journal of Roentgenology(AJR). 2007; 188(5):E140-A115.

Deveolpment of a PET/CT database of patient information and scanning parameters. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):199P/701.

PET/CT quality assurance in clinical trials and good clinical practice. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):448P/2012.

Diagnosis of venous obstruction and thrombosis by radionuclinde venography in patients with central venous catheters. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):212P/1019.

Practical methods to minimize occupational radiation exposures in PET and nuclear medicine. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):452 p/2024.

Inhibition of the heat Shock Protein 90(Hsp90) chaperone with the novel agent PIP-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase 1 trial. Journal of Clinical Oncology (JCO). 2007; 25(18S Part 1 of 2):551s/10024.

Inhibition and flare patterns of metabolic response to the heat shock protein 90(Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy. Journal of Clinical Oncology (JCO). 2007; 25(18S Part 1 of 2):145s/3530.

Lymphoma: Differentiation of Lymphoma from Other Conditions. American Journal of Roentgenology(AJR). 2007; 188(5):A125.

18FDG-PET/CT in Soft Tissue Sarcoma: Looking Beyond GIST. American Journal of Roentgenology(AJR). 2007; 188(5):E429-A191-A195.

Radiological Response and Toxicity of the New Targeted Molecular Therapies for Cancer-What the Radiologist Needs to Know. American Journal of Roentgenology(AJR). 2007; 188(5):E419 A191-A195.

Primary Malignant Neoplasms Mimicking Peritoneal Carcinomatosos: CT, MRI, and 18F FDG PET/CT Findings. American Journal of Roentgenology(AJR). 2007; 188(5):E207-A125-A140.

The Utility of 18F-FDG-PET in the Diagnosis and Management of Colorectal Carcinoma. Seminars in Colon and Rectal Surgery. 2007; In Press.

New core facility provides a common home for high-tech analysis of tumor images. Inside the Institute. 2007; 12(5):1.

Inhibiting TNFa with etanercept in relapsed/refractory follicular lymphoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):17525.
View in: PubMed

Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol. 2006 Jun 20; 24(18_suppl):9547.
View in: PubMed

Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):503.
View in: PubMed

Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST). J Clin Oncol. 2006 Jun 20; 24(18_suppl):3087.
View in: PubMed

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006 Jun; 47(6):1059-66.
View in: PubMed

Clonal Evolution of Resistance to Imatinib in Patients with Metastic GIST: Molecular and Radiologic Evaluation of New Lesions. 2006.

Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; San Francisco, CA. 2006.

Inhibiting TNF with etanercept in relapsed/refractory follicular lymphoma. American Society of Clinical Oncology (ASCO). 2006; 24:682s.

Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST). American Society of Clinical Oncology (ASCO). 2006; 24:142s.

FDG-PET imaging demonstrates metabolic response to SU11248 (sunitinib malate) within 7 days in GIST patients resistant to or intolerant of imatinib mesylate. ICACT. 2006; 17:241.

Pahe II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. American Society of Clinical Oncology (ASCO). 2006; 24:3s.

Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST). American Society of Clinical Oncology. 2006; 24:531s.

Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):3034.
View in: PubMed

Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). J Clin Oncol. 2005 Jun; 23(16_suppl):9006.
View in: PubMed

2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography of the head and neck: an atlas of normal uptake and variants. Mol Imaging Biol. 2005 May-Jun; 7(3):244-56.
View in: PubMed

Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005 Jun; 235(3):892-8.
View in: PubMed

Tumor Ablation: Principles and Practice. 2005; 121-134..

Qualitative assessment of FDG PET correlates with clinical benefit in patients with imatinib mesylate-resistant GIST treated with multi-targeted tyrosine kinase inhibitor SU11248. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; Hollywood, FL. 2005.

Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). American Society of Clinical Oncology (ASCO); Orlando, FL. 2005.

Seeing into cells: the promise of in vivo molecular imaging in oncology. 2005.

Positron Emission Tomography Imaging for Tumor Ablation. Tumor Ablation: Principles and Practice. 2005; 121-134..

FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate. The European Cancer Conference (ECCO 13); Paris, France. 2005.

Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2005 Jan 01; 61(1):175-84.
View in: PubMed

Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004 Oct; 26(10):890-6.
View in: PubMed

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004 Sep 01; 10(17):5732-40.
View in: PubMed

Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3011.
View in: PubMed

Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3002.
View in: PubMed

Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3010.
View in: PubMed

Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3012.
View in: PubMed

Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):9024.
View in: PubMed

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3001.
View in: PubMed

Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001)and imatinib mesylate (IM, Glivac/Gleevac) in patients with gastrointestinal stromal tumor (GIST)refractory to IM. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). New Orleans, LA. American Society of Clincal Oncology (ASCO) Conference. 2004.

Combination signal transduction inhibition: a phase 1 and 2 trial of the oral mTOR-inhibitor everolimus (ERAD001) and imatinib mesylate (IM, Glivac r/Gleevac r) in patients (pts) with gastrointestinal stromal tumor (GIST) refactory to IM. American Society of Clinical Oncology (ASCO) Conference. 2004.

Effects of cessation of imatinib mesylate therapy in patients with IM-refractory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.

Safety and efficacy of percutaneous Radio-Frequency Ablation (RFA)in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)with clonal evolution of lesions refractory to imatinib mesylate (IM). American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.

Effects of cesssation of imatinib mesylate (IM) therapy in patients (pts) with IM-refactory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning. American Soceity of Clinical Oncology (ASCO) Conference. 2004.

Clonal evaluation of resistance to imatinib in patients with gastrointestinal stromal tumor (GIST): Molecular and radiologic evaluation of new lesions. American Society of Clinical Oncology (ASCO)Conference. New Orleans, LA. 2004.

The era of molecular therapy: redifining the treatment of gastrointestinal stromal tumors (GIST). 2004.

Safety and efficacy of percutaneous Radio-Frequency Ablation (RFA)in patients (Pts) with metastatic gastrointestinal stromal tumor (GIST)with clonal evolution of lesions refractory to imatinib mesylate (IM). American Society of Clinical Oncology (ASCO) Conference. 2004.

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib (IM) resistance caused by stromal tumor (GIST). American Society of Clinical Oncology (ASCO)Conference. 2004.

Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST). Molecular and radiologic evalution of new lesions. American Society of clinical Oncology (ASCO) Conference. 2004.

Optimal management of patients with gastrointestinal stromal tumors (GIST). 2004.

NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2004 May; 2 Suppl 1:S-1-26; quiz 27-30.
View in: PubMed

Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Gastrointestinal Cancers Symposium; San Francisco, CA. 2004.

Long-term follow upof advanced gastrointestinal stromal tumors (GIST) patients treated with imatinib mesylate. Gastointestinal Cancers Symposium . 2004.

FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004 Jan; 45(1):85-92.
View in: PubMed

A CME newsletter publication covering key clinical issues in the management of GIST, including highlights from the 2003 CTOS annual meeting and Helsinki GIST symposium. 2004.

Use of Computerized Tomography as an Early Prognostic Indicator of Response to Imatinib Mesylate in Patient with Gastrointestinal Stromal Tumors (GIST). Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA. 2004.

Non-Hodgkin's Lymphomas. 2004; 155-169.

Activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU011248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; San Francisco, CA. 2004.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 01; 21(23):4342-9.
View in: PubMed

Physiologic and benign causes of FDG uptake in oncologic FDG-PET imaging. Radiological Society of North America (RSNA) Conference. Chicago, IL. 2003.

Physiologic and benign causes of FDG uptake in oncologic FDG-PET imaging. Radiological Society of North America (RSNA)Conference. 2003.

Evaluation of a Model Based Scatter Correction in Clinical 3D PET. IEEE Medical Imaging Conference. Portland, OR. 2003.

Prospective comparison of imaging findings in the lung, hilum and spleen on FDG-PET and GA-67 scintigraphy in patients with hodgkin's disease prior to and following chemotherapy with ABVD. Radiological Society of North America (RSNA) Conference. Chicago, IL. 2003.

Impact of patient size, acquisition mode, reconstruction algorithm, and randoms and attenuation corrections on lesion detection and activity estimation in whole-body FDG-PET. IEEE Medical Imaging Conference. Portland, OR. 2003.

Prospective comparison of imaging finding in the lung, hilum and spleen on FDG-PET and GA-67 scintigraphy in patients with hodgkin's disease prior to and following chemotherapy with ABVD. Radiological Society of North America (RSNA) Conference. . 2003.

Impact of patient size, aquisition mode, reconstruction algorithm, and randoms and attenuation corrections on lesion detection and activity estmiation in whole-body FDG-PET. IEEE Medical Imaging Conference. 2003.

Evaluation of a Monte Carlo scatter correction in clinical 3D PET. IEEE Medical Imaging Conference. 2003.

Impact of patients size, Acquisition mode, reconstruction algorithm, and random and attenuation corrections on lesion detection and activity estimation in whole-body FDG-PET. IEEE Medical Imaging Conference. 2003.

Assessing biological responses to SU11248 in a Phase I clinical trial of patients with imatinib -resistant gastrointestinal stromal tumors (GIST):. Pharmacodynamic evaluation using 18 FDG-PET functional imaging, pharmacokinetics, and modulation of blood biomarkers. 2003.

Assessing biological responses to SU11248 in a Phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Pharmacodynamic evaluation using FDG-PET functional imaging, pharmacokinetics, and modulation of blood biomarkers. ISMRM Workshop on Cellular and Molecular Imaging in Diagnostics and Therapy. Orlando, FL. 2003.

Medical Progress, Esophageal Cancer. New Engl. J. Med. 2003.

Biological activity of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal Stromal tumor (GIST)refractory to imatinib mesylate. AACR. 2003; 44:967.

Dependence of performace of whole-body-FDG-PET lesion detection and activity estimation on patient size, randoms, variance reduction, and acquisition geometry. J Nucl Med. 2003; 44(5):61.

Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol. 2003; 22:814A.

Molecular-genetic imaging: current and future perspective. 2003.

Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol. 2003; 22:192A.

Novel patterns of progression following initial response to Imatinib in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2003; 22:230A.

FDG-PET as a Surrogate Marker for the Response to Gleevec (Imatinib Mesylate) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST). J Nucl Med. 2003; 44(5):24-25.

Radiographic Evaluation of Cancer. Atlas of Diagnostic Oncology. 2003; 5-26.

Non-Hodgkin's Lymphomas. Nuclear Medicine. 2003.

Pet Imaging: Tumor Ablation: Principles and Practice. 2003.

A New Role for PET Scanning. The American Journal of Oncology Reivew. 2003; 367-368.

Decreases in circulating levels of soluble KIT in patients with imatinib-resistant gastrointestinal Stromal tumor (GIST) receiving the novel kinases inhibitor SU11248: Correlative analysis of blood and plasma biomarkers. AACR. 2003; 44:587.

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002 Sep; 38 Suppl 5:S60-5.
View in: PubMed

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80.
View in: PubMed

A Pilot study of Imatinib Mesylate (Gleevec) prior to prostatectomy in men with newly diagnosed prostate cancer. CaPCURE Scientific Retreat. 2002.

The role of FDG-PET in patients with squamous cell cancer of the head and neck after sequential induction chemotherapy and definitive chemoradiotherapy. J Nucl Med. 2002; 43:P73.

FDG-PET as a key tool in the diagnosis and monitoring of GIST. In first Successful Treatment for GIST. 2002.

A Pilot study Imatinib Mesylate prior to prostatectomy in men with newly diagnosed prostate cancer. 2002.

The use of FDG-PET to detect residual disease after induction chemotherapy and definite chemoradiotherapy for squamous cell cancer of the head and neck. Sixth Research Workshop on the Biology,Prevention, and Treatment of Head and Neck Cancer. 2002.

FDG-PET is superior to gallium-67 scintigraphy in the staging and follow-up of patients with Hodgkin's disease: a prospective, blinded comparison. J Nucl Med. 2002; 43:P30-P31.

PET imaging and treatment evaluation in cancer patients. 2002.

Impact of acquisition geometry and lesion size on tumor detectability in patient whole body PET: A channelized hotelling observer study. IEEE meeting. 2002.

PET. Medstar. 2002.

A comparison of 2D and 3D FDG-PET images on a high performance BGO scanner using an interleaved septa-in/septa-out acquisition protocol. Molecular Imaging and Biology. 2002; 4:44S.

Impact of acquisition geometry and size on tumor detectability in patient whole body PET:. A Channelized hotelling observer study. 2002.

Response to imatinib mesylate (Gleevec) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT. Radiology. 2002; 225:P424.

F-FDG-PET predicts response to Imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2002; 21:P403a.

A day in the life of the Dana-Farber Cancer Institute. 2001.

The use of FDG-PET to detect residual disease after sequential therapy with induction chemotherapy and definitive chemoradiotherapy for squamous cell cancer of the head and neck. The second International Chicago Symposium on Malignancies of the Chest and Head and neck. 2001.

The use of FDG-PET to detect residual disease after sequential therapy with induction chemotherapy and definitive chemoradiotherapy for squamous cell cancer of the head and neck. The Second International Chicago Symposium on Malginancies of the Chest and Head & Neck. 2001; abst. 76.

A prospective blinded comparison of positron emission tomography(PET)with gallium/SPECT scintigraphy in the staging and follow-up of patients with de novo Hodgkin's disease. International Lymphoma Conference, Lausanne. 2001.

A prospective blind comparison of positron emission tomography (PET) with gallium/SPECT scintigraphy in the staging and follow up of patients with de novo Hodgkin's disease. 2001.

GIST tumors and Glivec. 2001.

The role of PET in patients with cancer. 2001.

The role of PET in patients with GIST. 2001.

A potential murine model for flap-related investigations. Plast Reconstr Surg. 2001 May; 107(6):1504-8.
View in: PubMed

Breast Cancer. 2001.

F18-FDG-PET provides early evidence of biological response to ST1571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2001; 20:P362a.

PET documents Gleevec tumor-fighting power. Diagnostic Imaging. 2001; 1(2):4.

Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer. 2001 Jan 01; 91(1):17-24.
View in: PubMed

The Power of Positron Emission Tomography (PET). 2001.

The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis. 2000 Dec; 10(3):271-5.
View in: PubMed

Uncovering Cancer. The use of radioactive tracers. 2000.

PET scanners. 2000.

When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy? J Nucl Med. 2000 Feb; 41(2):269-74.
View in: PubMed

Relative Lesion detectability in 3D vs. 2D dedicated multi-ring PET. 2000.

The use of FDG-PET to detect residual disease after induction chemotherapy and definite chemoradiotherapy for squamous cell cancer of the head and neck. Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer. Virginia. 2000.

Relative lesion detectability in 3D vs. 2D dedicated multi-ring PET. IEEE meeting 2000, Lyon, France. 2000.

Advances at the Frontier of Cancer Diagnosis: PET scanner opens a window on cancer. Paths of Progress. 2000.

PET scanner is enhancing cancer diagnosis. 2000.

Lymphoscintigraphy. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele A. 2000; 369-374.

Positron Emission Tomography (PET). 2000.

Vascular Scintigraphy. Teaching Atlas of Nuclear Medicine. 2000; 429-439.

Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele. 2000; 235-246.

Teaching Atlas of Nuclear Medicine. 2000.

Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. 2000; 199-216.

Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele. 2000; 224-234.

Large and multiple hepatic lesions: Strategies and rationale for radiologic tumor ablation. RSNA Annual Meeting. 2000.

Large and multiple hepatic Lesions. Strategies and rationale for radiologic tumor ablation. 2000.

Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999 Oct 15; 86(8):1621-7.
View in: PubMed

Return of lymphatic function after flap transfer for acute lymphedema. Ann Surg. 1999 Mar; 229(3):421-7.
View in: PubMed

Primary cardiac angiosarcoma presenting as a malignant pericardial effusion. J Clin Oncol. 1998 Dec; 16(12):3913-5.
View in: PubMed

5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med. 1998 Jul; 39(7):1148-54.
View in: PubMed

Biodistribution of radiolabeled MOv18 in nude mice bearing ovarian cancer xenografts. Proceeding of the Fourth International Conference on Monoclonal Antibody lmmunoconjugates for Cancer. 1998; 97.

Comparison of Dual-Head Gamma Camera System Sensitivity at 511 keV using a Distance-Dependent Method. American Association of Physicists in Medicine 39th Annual Meeting and Exhibition. Milwaukee, WI. 1997.

Comparison of Dual-Head Gamma Camera System Sensitivity at 511 KeV using a Distance-Dependent Method. American Association of Physicists in Medicine a 39th Annual Meeting and Exhibition. 1997.

Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. Society of Nuclear Medicine. J Nucl Med. 1997 Jun; 38(6):990-4.
View in: PubMed

An investigation of lymphatic function following free-tissue transfer. Plast Reconstr Surg. 1997 Mar; 99(3):730-41; discussion 742-3.
View in: PubMed

Quantification of gallium-67 avidity as a function of the histology in patients with non-Hodgkin's lymphoma. J Nucl Med. 1997; 38:P238.

The role of SPECT in the evaluation of the abdomen on gallium-67 scintigraphy. J Nucl Med. 1997; 38:P115.

Determinination of the visibility of simulated lesions in background with 511 KeV SPECT. Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology PET and Cancer. 1996.

Determination of the visibility of simulated lesions in background with 511 keV SPECT. European Conference on Research and Application of Positron Emission Tomography in Oncology PET and Cancer, Groningen University Hospital, The Netherlands. 1996.

Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med. 1996 Apr; 37(4 Suppl):19S-22S.
View in: PubMed

Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med. 1996 Feb; 37(2):315-20.
View in: PubMed

Lymphoscintigraphy. 1996.

Thallium-201 scintigraphy in low grade non-Hodgkin's lymphoma. J Nucl Med. 1996; 37:P258.

Octreotide scintigraphy. 1996.

Determination of the visibility of simulated lesions in background with 511 KeV SPECT. In Paans AMJ, Pruim J, Franssen EJF, Vaalburg W, eds.+. Metabolic imaging of cancer. Proceedings of the Europeans Conference on Research and Application of Positron Emission Tomography in Oncology. 1996.

A world wide web-based resource for the physical evaluation of 511 keV-collimated imaging. J Nucl Med. 1996; 37:P305.

Scrontium-89 radiotherapy for painful bony metastases. 1996.

A Patient Guide to Nuclear Medicine at the Dana-Farber Cancer Institute. Divsion of Nuclear Medicine at the DFCI. 1996.

Scrontium-89 radiotherapy for painful bony metastases. 1996.

Tumor and Inflammatory conditions. 1996.

Classification of upper extremity lymphedema via lymphoscintigraphy. J Nucl Med. 1996; 37:P261.

Intratumoral administration of 5-[123/]iodo-2-deoxyurdine in a patients with a brain tumor. Adelstein SJ, Kassis AI, eds. Processing of symposium on clinical application of radiolabeled IUdR. 1996; 37:(Suppl) 19S-22S.

pI-dependent isolation of antibody isoforms by semipreparative isoelectric focusing. Q J Nucl Med. 1995 Jun; 39(2):129-33.
View in: PubMed

Inflammation and infection. Pediatric Nuclear Medicine. 1995; 540-549.

Scintigraphy of lymphoma. 1995.

Lymphatic imaging and its multiple roles in clinical practice. J Nucl Med. 1995; 36:P222.

Monoclonal antibodies: A review of the basics. 1994.

Modification of Mouse IgG isoelectric point following radioiodination. Antibody Immunoconj Radiophar. 1994; 7:171-178..

Tumor targeting potential and metabolism of 5-[125I]iodo-2'-deoxyuridine injected intratumorally in patients with breast cancer. Ann N Y Acad Sci. 1993 Nov 30; 698:204-11.
View in: PubMed

A new three-step strategy using the avidin-biotin system for radioimaging tumors. Abstracts of the Tenth International Symposium on Radiopharmaceutical Chemistry, Kyoto, Japan. 1993; 392(3).

A new three-step strategy using the avidin-biotin system for radioimaging tumors. Abstracts of the Tenth International Symposium in Radiopharmaceutical Chemistry,. 1993; 392-3.

Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med. 1993 Jul; 34(7):1175-83.
View in: PubMed

A three-step procedure for the targeting of tumors using the avidin-biotin system. Presented at the Australia/ New Zealand Society of Nuclear Medicine scientific Meeting. 1993.

A three-step procedure for the targeting of tumors using the avidin-biotin system. Australia/New Zealand Society of Nuclear Medicine Scientific Meeting, Canberra, Australia. 1993.

Monoclonal antibodies: From basics to clinical implementation. 1993.

Tumor targeting potential and metabolism of 5-[125]iodo 2-deoxyuridine injected intratumorally in patients with breast Cancer. Ann NY Acad sc. 1993; 698:204-11.

Intratumoral injection of 5[123]iodo-2-dexyuridine in patients with breast cancer. In Hofer R, Bergmann H, Sinzinger H, eds. Radioactive isotopes in clinical medicine and research. 1993; 188-93.

N-(m-[125I]iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies. Int J Rad Appl Instrum B. 1992 Apr; 19(3):289-95.
View in: PubMed

Diagnostic and therapeutic application of Auger-electrons-emitting 5[123/125]iodo-2-deoxyuridine in cancer. In Howell RW, Narra VR, Sastry KSR, Rao DV, eds Biophysical aspect of Auger processes, AAPM Symposium Proceeding number 8. 1992; 372-395.

Tumor targeting potential and metabolism of 5-[125]iodo-2-deoxyurdine injected intratumorally in patients with gastrointestinal or breast cancers. J Nucl Biol Med. 1992; 154-7.

5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys. 1991 Nov; 21(6):1541-51.
View in: PubMed

Diagnostic and therapeutic applications of the Auger electron-emitting 5-[123/125/]iodo-2'-deoxyuridine in cancer. Second International Symposium on Biophysical Aspects of Auger Processes, Amherst, MA. 1991.

Diagnostic and therapeutic applications of the Auger electrons-emitting 5-[123/125/]iodo-2-deoxyuridine in cancer. Presented at the Second International Symposium on Biophysical Aspect of Auger Processes, Amherst. 1991.

Embolization of platelets after endothelial injury to the aorta in rabbits. Assessment with 111indium-labeled platelets and angiography. Invest Radiol. 1991 Jul; 26(7):655-9.
View in: PubMed

Capping and internalization of a monoclonal antibody-surface antigen complex: a possible mode of interaction of monoclonal antibodies and tumor cells. J Nucl Biol Med. 1991 Apr-Jun; 35(2):111-9.
View in: PubMed

Antigen-binding site protection during radiolabeling leads to a higher immunoreactive fraction. J Nucl Med. 1991 Jan; 32(1):116-22.
View in: PubMed

Potential for tumor therapy with iodine-125 labeled immunoglobulins. Int J Rad Appl Instrum B. 1991; 18(1):43-4.
View in: PubMed

Detection of focal infection by 111In-human polyclonal IgG. J Nucl Biol Med. 1991 Jan-Mar; 35(1):4-9.
View in: PubMed

Potential for tumor therapy with iodine-125 labeled immunoglobulins. Nucl Medicine Biol. 1991; 18:43-4.

Platelet activation and aggregation after endothelial injury. Assessment with indium-111-labeled platelets and angiography. Invest Radiol. 1990 Sep; 25(9):988-93.
View in: PubMed

Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res. 1990 Aug 15; 50(16):5199-203.
View in: PubMed

Inhomogeneous deposition of radiopharmaceuticals at the cellular level: experimental evidence and dosimetric implications. J Nucl Med. 1990 Aug; 31(8):1358-63.
View in: PubMed

Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res. 1990 Apr 01; 50(7):2198-202.
View in: PubMed

Preadsorption of radiolabeled monoclonal antibodies to liver and spleen tissues leads to higher tumor-to-normal-tissue ratios. J Nucl Med Allied Sci. 1990 Apr-Jun; 34(2):94-102.
View in: PubMed

Microscopic spatial inhomogeneity of radiopharmaceutical deposition in mammalian tissues: dosimetry at the cellular level and comparison with conventional dosimetry. Radiat Prot Dosim. 1990; 31:319-24..

Autoradiographic validation of 5-[123/125/] iodo-2'-deoxyurdine as a diagnostic and therapeutic agent for brain tumors. J Nucl Med,. 1990; 31(766).

Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. Am J Obstet Gynecol. 1989 Nov; 161(5):1206-12.
View in: PubMed

Absence of preferential uptake of [125I]iododihydrorhodamine 123 by four human tumor xenografts. Cancer Res. 1989 Nov 01; 49(21):5986-8.
View in: PubMed

Biodistribution of radiolabeled MOv18 in nude mice bearing ovarian cancer xenografts. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA. 1989; 97.

Radiolabeled biodegradable membranes for radioimmunotherapy. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA. 1989; 98.

Radiolabeled biodegradable membranes for radioimmunotherapy. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer. 1989; 98.

Internalization of monoclonal 3G5-IgM by a rat insulinoma cell line. Nuclear medicine: trends and possibilities in nuclear medicine. 1989; 602-605.

Monoclonal antibody internalization by tumor cells: an experimental model for potential radioimmunotherapy applications. Int J Rad Appl Instrum B. 1989; 16(2):147-50.
View in: PubMed

Does the in vitro testing of the immunoreactivity of an antibody reflect its in vivo behavior? J Nucl Med Allied Sci. 1988 Oct-Dec; 32(4):260-7.
View in: PubMed

HPLC analysis of the dissociation and recombination of rabbit immunoglobulin G. J Immunol Methods. 1987 Feb 11; 96(2):195-9.
View in: PubMed

The role of granulocytes in the pulmonary response to group B streptococcal toxin in young lambs. Pediatr Res. 1987 Feb; 21(2):159-65.
View in: PubMed

Bone metastases in Zollinger-Ellison syndrome: detection by bone scintigraphy. Clin Nucl Med. 1987; 12:954-5..

Vesicoureteral reflux in asymptomatic siblings of patients with known reflux: radionuclide cystography. Pediatrics. 1987 Jan; 79(1):147-53.
View in: PubMed

Parathyroid scintigraphy. Division of Nuclear Medicine, Beth Israel Hospital, Harvard Medical School. 1986; 7(2).

Effect of alcohol on apnea reflexes in young lambs. J Appl Physiol (1985). 1985 Aug; 59(2):420-5.
View in: PubMed

Leukocyte labeling with isonitrile complexes of technetium-99m. J Nucl Med. 1985; 26:P131.

Lung lymph studies in newborn lambs with hyaline membrane disease. The physiological development of the fetus and newborn. 1985; 331-335.

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Top